Tim Wilsdon recently presented at a forum on “Buying for Value Globally: Can We Make it Work? “ during the Medtech Conference in San Jose. He presented on-going work developing a landscape analysis for medical devices.
For more information on the conference, click here.
CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...